Lynne Bui
Director/Board Member at THARIMMUNE, INC.
Net worth: - $ as of 2024-04-29
Profile
Lynne A Bui is the founder of Khloris Biosciences, Inc., Global Cancer Research Institute, GCRI Foundation, Inc. She is currently an Independent Director at Tharimmune, Inc. Her former positions include Chief Medical Officer at Onyx Pharmaceuticals, Inc., Exelixis, Inc., and Intellikine LLC.
She received her undergraduate degree from the University of California, Berkeley and her graduate degree from David Geffen School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
THARIMMUNE, INC.
-.--% | 2024-03-20 | 0 ( -.--% ) | - $ | 2024-04-29 |
Lynne Bui active positions
| Companies | Position | Start |
|---|---|---|
| THARIMMUNE, INC. | Director/Board Member | 2021-06-30 |
Khloris Biosciences, Inc.
 Khloris Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Khloris Biosciences, Inc. operates as biotechnology company. The firm offers drug discovery, vaccine and cell therapies for treatment and prevention of cancer. The company was founded by Lynne A. Bui and Joseph C. Wu in June 2017 and is headquartered in Mountain View, CA. | Chief Executive Officer | 2017-05-31 |
| Global Cancer Research Institute | Founder | - |
| GCRI Foundation, Inc. | Founder | - |
Former positions of Lynne Bui
| Companies | Position | End |
|---|---|---|
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | - |
Intellikine LLC
 Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Chief Tech/Sci/R&D Officer | - |
| EXELIXIS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Lynne Bui
| University of California, Berkeley | Undergraduate Degree |
| David Geffen School of Medicine | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| THARIMMUNE, INC. | Health Technology |
| EXELIXIS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Khloris Biosciences, Inc.
Khloris Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Khloris Biosciences, Inc. operates as biotechnology company. The firm offers drug discovery, vaccine and cell therapies for treatment and prevention of cancer. The company was founded by Lynne A. Bui and Joseph C. Wu in June 2017 and is headquartered in Mountain View, CA. | Commercial Services |
| Global Cancer Research Institute | |
| GCRI Foundation, Inc. | |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Intellikine LLC
Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Health Technology |
- Stock Market
- Insiders
- Lynne Bui
